People With Type 2 Diabetes Who Were Increased to Semaglutide 2 Mg Were as Likely to Achieve an Hba1c Less Than 7% and More Likely to Achieve Greater Than 5% Weight Loss Than Those Who Were Switched to Tirzepatide, in Real-World Data
THOMSON REUTERS06-06 21:01
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments